Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101

Neoplasia

Volumn 6, Issue 3, 2004, Pages 213-223

  Kiessling, Fabian ^a   Farhan, Nabeel ^a   Lichy, Matthias P ^a   Vosseler, Silvia ^a   Heilmann, Melanie ^a   Krix, Martin ^a   Bohlen, Peter ^b   Miller, Dan W ^c   Mueller, Margareta M ^a   Semmler, Wolfhard ^a   Fusenig, Norbert E ^a   Delorme, Stefan ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Angiogenesis; DC101; DCE MRI; Tumor; VEGF

Indexed keywords

CD31 ANTIGEN; GADOLINIUM PENTETATE; MONOCLONAL ANTIBODY DC101; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; RECEPTOR BLOCKING; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 2442716283     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.3394     Document Type: Article

References (45)

1. Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
2. Folkman J (2001). Angiogenesis-dependent diseases. Semin Oncol 28, 536-542.
3. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31.
4. Fox SB, Gasparini G, and Harris AL (2001). Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2, 278-289.
5. Scappaticci FA (2002). Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20, 3906-3927.
6. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, and Thorpe PE (2000). Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60, 5117-5124.
7. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, and Nakamura T (2000). HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60, 6737-6743.
8. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, and Kerbel RS (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105, 15-24.
9. Gasparini G (2001). Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2, 733-740.
10. Jain RK (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987-989.
11. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin D, Bohlen P, and Kerbel S (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Clin Invest 105, R15-R24.
12. Kerbel RS (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis 21, 505-515.
13. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, and Wiegand SJ (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoeitins and VEGF. Science 284, 1994-1998.
14. Thomas KA (1996). Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 271, 603-606.
15. Neufeld G, Cohen T, Gengrinovitch S, and Poltorak Z (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13, 9-22.
16. Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, and Choyke P (2001). Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 12, 301-308.
17. Padhani R and Husband JE (2001). Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56, 607-620.
18. Lyng H, Dahle GA, Kaalhus O, Skretting A, and Rofstad EK (1998). Measurement of perfusion rate in human melanoma xenographs by contrast enhanced magnetic resonance imaging. Magn Reson Med 40, 89-98.
19. Abramovitch R, Dafni H, Neeman M, Nagler A, and Pines M (1999). Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1, 321-329.
20. Neeman M, Provenzale JM, and Dewhirst MW (2001). Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. Semin Radiat Oncol 11, 70-82.
21. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, and Solaiyappan M (2001). Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 3, 143-153.
22. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L, and Decorps M (2001). Vessel size imaging. Magn Reson Med 45, 397-408.
23. Hoffmann U, Brix G, Knopp MV, Hess T, and Lorenz WJ (1995). Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 33, 506-514.
24. Port RE, Knopp MV, Hoffmann U, Milker-Zabel S, and Brix G (1999). Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging 10, 233-241.
25. Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schonberg SO, Vaupel P, and van Kaick G (1998). Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4, 2305-2312.
26. Hawighorst H, Knapstein PG, Knopp MV, Vaupel P, and van Kaick G (1999). Cervical carcinoma: standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Magma 8, 55-62.
27. Moehler TM, Hawighorst H, Neben K, Egerer G, Hillengass J, Max R, Benner A, Ho AD, and van Kaick G (2001). Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer 93, 862-868.
28. Abramovitch R, Meir G, and Neeman M (1995). Neovascularization induced growth of implanted C6 glioma multicellular spheroids: magnetic resonance microimaging. Cancer Res 55, 1956-1962.
29. Weissleder R, Bogdanov A, Tung CH, and Weinmann HJ (2001). Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging. Bioconjug Chem 12, 213-219.
30. Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, Tarlo KS, Wendland MF, and Brasch RC (2001). MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology 218, 562-569.
31. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, and Melnyk O (1997). Assessing tumor angiogenesis using macromolecular MR imaging contrast media. Magn Reson Imaging 7, 68-74.
32. Kiessling F, Fink C, Hansen M, Bock M, Sinn H, Schrenk HH, Krix M, Egelhof T, Fusenig NE, and Delorme S (2002). Magnetic Resonance Imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas (SCC): use of a low loaded, covalently bound Gd-HSA conjugate as contrast agent with high tumor affinity. J Invest Radiol 37, 193-198.
33. Skobe M, Rockwell P, Goldstein N, Vosseler S, and Fusenig NE (1997). Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3, 1222-1227.
34. Fusenig NE and Boukamp P (1998). Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. J Mol Carcinog 23, 144-158.
35. Mueller M, Peter W, Mappes M, Huelsen A, Steinbauer H, Boukamp P, Vaccariello M, Garlick J, and Fusenig NE (2001). Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 159, 1567-1579.
36. Brix G, Semmler W, Port R, Schad LR, Layer G, and Lorenz WJ (1991). Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput-Assist Tomogr 15, 621-628.
37. Kiessling F, Heilmann M, Vosseler S, Lichy M, Krix M, Fink C, Kiessling I, Steinbauer H, Schad L, Fusenig NE, and Delorme S (2003). T1-dynamic monitoring of vascularization in human carcinoma heterotransplants by magnetic resonance imaging. Int J Cancer 104, 113-120.
38. Kiessling F, Krix M, Heilmann M, Vosseler S, Lichy M, Fink C, Farhan N, Kleinschmidt K, Schad L, Fusenig NE, and Delorme S (2003). Comparing dynamic parameters of tumor vascularisation in nude mice revealed by MRI and intermittent power Doppler sonography. Invest Radiol 38, 516-524.
39. Kaplan HM, Brewer NR, and Blair WH (1983). The Mouse in Biomedical Research. In Foster, HL, Small, JD, Fox, JG (Eds.), p. 251 Academic Press, New York.
40. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Brasch RC, and Steward WP (2003). Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21, 3955-3964.
41. Krix M, Kiessling F, Vosseler S, Farhan N, Bohlen P, Fusenig NE, and Delorme S (2003). Monitoring tumor perfusion during antiangiogenic therapy with intermittent bolus-contrast power Doppler sonography. Cancer Res (in press).
42. Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TPL, Shames DM, van Bruggen N, Wendland MF, Israel MA, and Brasch RC (2002). Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 15, 233-240.
43. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, and Melnyk O (1997). Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 7, 68-74.
44. Bogdanov AA, Lewin M, and Weissleder R (1999). Approaches and agents for imaging the vascular system. Adv Drug Deliv Rev 37, 279-293.
45. Gossmann A, Okuhata Y, Shames DM, Helbich TH, Roberts TPL, Wendland MF, Huber S, and Brasch RC (1999). Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media-preliminary experience. Radiology 213, 265-272.